Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Yejong Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8532-9531; OpenAlex author ID A5080577768, A5125662157. Sources: OpenAlex.

Their work

Papers
28 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2019: 1 paper · 2020: 5 papers · 2021: 8 papers · 2022: 2 papers · 2023: 3 papers · 2024: 5 papers · 2025: 2 papers · 2026: 2 papers

Papers 28

  1. Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal … Co-author DOI 10.1007/s00464-025-12452-3↗
  2. Clinical outcomes of completing total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreat… Co-author DOI 10.1016/j.surg.2026.110088↗
  3. Applicability of current nodal staging system for resected pancreatic cancer after neoadjuvant therapy: a retrospective study. Co-author DOI 10.1016/j.hpb.2025.04.011↗
  4. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experie… Co-author DOI 10.1016/j.surg.2025.109331↗
  5. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant … Co-author DOI 10.1016/j.ejso.2024.108494↗
  6. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  7. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  8. Prognostic model for resected borderline and locally advanced pancreatic cancer after neoadjuvant chemotherapy. Co-author DOI 10.1097/js9.0000000000001927↗
  9. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.977↗
  10. Robotic versus laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1016/j.hbpd.2022.06.001↗
  11. Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002218↗
  12. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  13. Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10641-7↗
  14. Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfron… Co-author DOI 10.21037/gs-22-304↗
  15. A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis. Co-author DOI 10.1002/jhbp.853↗
  16. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-80383-1↗
  17. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  18. Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadren… First author DOI 10.3390/biomedicines9101291↗
  19. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker… Co-author DOI 10.3390/biomedicines9111599↗
  20. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. First author DOI 10.3390/biomedicines9111706↗
  21. Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm10245784↗
  22. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i11.1423↗
  23. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. First author DOI 10.1038/s41598-020-68703-x↗
  24. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients. Co-author DOI 10.1097/md.0000000000022115↗
  25. Comparison of Minimally Invasive Versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis. Co-author DOI 10.3390/cancers12040982↗
  26. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… First author DOI 10.3390/jcm9051477↗
  27. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9061953↗
  28. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer. First author DOI 10.21873/anticanres.13206↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ki Byung Song · 28 shared papers, 2019–2026 · strength 4.53
  2. Dae Wook Hwang · 28 shared papers, 2019–2026 · strength 4.53
  3. Woohyung Lee · 25 shared papers, 2020–2026 · strength 4.04
  4. Song Cheol Kim · 24 shared papers, 2020–2026 · strength 3.78
  5. Eunsung Jun · 15 shared papers, 2020–2026 · strength 2.53
  6. Min Kyu Sung · 8 shared papers, 2021–2025 · strength 1.50
  7. Jaewoo Kwon · 12 shared papers, 2019–2023 · strength 1.40
  8. Bong Jun Kwak · 8 shared papers, 2021–2024 · strength 1.27
  9. Sarang Hong · 8 shared papers, 2020–2023 · strength 1.01
  10. Changhoon Yoo · 7 shared papers, 2019–2024 · strength 0.96
  11. Kyu‐pyo Kim · 6 shared papers, 2020–2024 · strength 0.87
  12. Baek‐Yeol Ryoo · 6 shared papers, 2020–2024 · strength 0.87
  13. Dakyum Shin · 5 shared papers, 2020–2023 · strength 0.69
  14. Seung‐Mo Hong · 2 shared papers, 2024 · strength 0.36
  15. Song Cheol Kim · 1 shared paper, 2026 · strength 0.33
  16. Inkeun Park · 2 shared papers, 2024 · strength 0.33
  17. Song Cheol Kim · 2 shared papers, 2021–2024 · strength 0.32
  18. Do Hyun Park · 2 shared papers, 2023–2024 · strength 0.30
  19. Jin‐hong Park · 2 shared papers, 2023–2024 · strength 0.30
  20. Tae Jun Song · 2 shared papers, 2023–2024 · strength 0.30
  21. Dong Wan Seo · 2 shared papers, 2023–2024 · strength 0.30
  22. Sang Soo Lee · 2 shared papers, 2023–2024 · strength 0.30
  23. Dongwook Oh · 2 shared papers, 2023–2024 · strength 0.30
  24. Seung Jae Lee · 2 shared papers, 2020–2022 · strength 0.27
  25. Woohyung Lee · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.